China Immunotech (Beijing) Biotechnology Co., Ltd. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 0 with minor changes only.
- Notable: YTS109 Cell Injection · Recurrent/Refractory Autoimmune Disease Primary and study completion dates pushed to Apr 21, 2027
- Notable: YTS109 Cell in R/R Autoimmune Diseases Primary completion pushed from May 19, 2026 to May 19, 2027
- Notable: YTS109 Cells · R/R Autoimmune Diseases Primary completion pushed from Aug 13, 2026 to Aug 13, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 6 |
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials
Lupus (SLE) (6) · Scleroderma (4) · Rheumatoid Arthritis (1)
Get alerts when China Immunotech (Beijing) Biotechnology Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.